Apr 13, 2009 - XenoPort, Inc. announced today that it has exercised the option contained in its Development and Commercialization Agreement with GlaxoSmithKline to co-promote and share profits and losses from the potential future sales of Solzira™ (gabapentin enacarbil) Extended Release Tablets in the United States.
The details can be read here.
No comments:
Post a Comment